New developments in molecular NET imaging range from the combination of F-18 FDG and Ga-68 DOTATOC to characterize different tumors and their aggressiveness to promising new tracers such as Glucagon-Like-Peptide-1 (GLP-1) receptor or somatostatin receptor antagonists tracers.26,27 Depending on the clinical problem not all examinations need to have the best tumor detection or the best tumor to background ratio. This evidence concerns the gene GLP1R and neoplasm.